You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

Pegasys (peginterferon alfa-2a)

In 2005, the US Food and Drug Administration (FDA) approved PEGASYS for the treatment of chronic hepatitis B. Already the most prescribed hepatitis C medication in the United States, PEGASYS is the first and only pegylated interferon approved for the treatment of chronic hepatitis B, including both main types of the virus.

PEGASYS helps in two important ways:

- PEGASYS slows replication of the hepatitis B virus.
- PEGASYS boosts the body's immune system.

Pegasys Product Information
(Pegasys for treatment of Hepatitis B starts on page 25 of PDF)

HBV Pegasys Roche Web Page


Articles on Pegasys (peginterferon alfa-2a) for Treatment of Hepatitis B


One-quarter of Patients Clear Hepatitis Delta with Pegylated Interferon
1-28-2011

Pegylated Interferon Has Low Sustained Response Rate in HBeAg Negative Chronic Hepatitis B Patients
9-17-2010

HBV DNA Decline at 24 Weeks Predicts Sustained Response to Pegylated Interferon for Chronic Hepatitis B
8-20-2010

HBV DNA Decline at 24 Weeks Predicts Sustained Response to Pegylated Interferon for Chronic Hepatitis B
6-25-2010


How Long Do Chronic Hepatitis B Patients Need to be Treated to Sustain HBeAg Seroconversion?
6-25-2010

HBeAg Decrease during Treatment Predicts Sustained Response to Pegylated Interferon for Chronic Hepatitis B
6-08-2010


Longer Treatment with Pegylated Interferon Works Better for Hepatitis B Genotype D
5-07-2010


HBV DNA and HBsAg Levels Predict Likelihood of Sustained Response to Pegylated Interferon for Hepatitis B
4-30-2010


Factors that Predict Response to Pegylated Interferon in HBeAg Positive Chronic Hepatitis B Patients
1-05-2010


Review Finds Pegylated Interferon Is More Effective than Lamivudine for Chronic Hepatitis B, but Study Shows Little Activity against HBV Genotype D
11-17-2009


Early HBsAg Decline Predicts Sustained Response to Pegylated Interferon; Extended Treatment Can Improve Outcomes
11-13-2009


Sustained Response in HBeAg Negative Chronic Hepatitis B Patients 3 Years After Treatment with Pegasys
8-08-2009

Pegylated Interferon Monotherapy for Treatment of Chronic Hepatitis B
4-07-2009

Sustained HBeAg and HBsAg Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon
9-26-2008

Pegylated Interferon Alfa-2a (Pegasys) Continues to Suppress HBV, but Adding Adefovir (Hepsera) Provides No Extra Benefit in PEG for B Trial
6-03-2008

Response to Pegylated Interferon in Adolescents with Chronic Hepatitis B
5-23-2008

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 Google Custom Search
FDA-approved Therapies for Chronic HBV Infection
Baraclude  (entecavir)
Epivir-HBV
  (lamivudine; 3TC)
Hepsera
  (adefovir dipivoxil)
Intron A  (interferon alfa-2b)
Pegasys  (peginterferon alfa-2a)
Viread  (tenofovir)
Tyzeka   (telbivudine)

Experimental Treatments

HBV Articles by Topic

Cirrhosis
Fibrosis
Hepatocellular Carcinoma
Liver Transplantation

Steatosis
Children / Infants / Women
Hepatitis B Clinical Trials
Experimental Treatments
FAQs About Hepatitis
Genotypes
Guidelines
Tests for HBV
Vaccines for HBV